Evidence map›Paper›PMID 33010835›Full record

ArticleLancet (London, England)2020

Remdesivir and COVID-19 - Authors' reply.

Yeming Wang, Xiaoying Gu, Jiuyang Xu, Bin Cao, Chen Wang

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Yeming WangDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China.
Xiaoying GuInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China.
Jiuyang XuTsinghua University School of Medicine, Beijing, China.
Bin CaoDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China. Electronic address: caobin_ben@163.com.
Chen WangDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsCoronavirus InfectionsPandemicsPneumonia, ViralRibonucleotidesAdenosine MonophosphateAlanineBetacoronavirusCOVID-19COVID-19 Drug TreatmentHumansSARS-CoV-2Adenosine MonophosphateAlanineAntiviral AgentsremdesivirRibonucleotides

Identifiers

PMID33010835
PMCPMC7529378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.